Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
MOMA Therapeutics
Eli Lilly and Company
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The New York Proton Center
Eli Lilly and Company
Nammi Therapeutics Inc
National Cancer Institute (NCI)
Beijing Biotech
Parabilis Medicines, Inc.
Fred Hutchinson Cancer Center
Exscientia AI Limited
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Alliance for Clinical Trials in Oncology
Centre hospitalier de l'Université de Montréal (CHUM)
Conjupro Biotherapeutics, Inc.
Zumutor Biologics Inc.
AstraZeneca
Agenus Inc.
858 Therapeutics, Inc.